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Cholesterol feeding accentuates the cyclosporine-induced elevation of
renal plasminogen activator inhibitor type 1. Long-term cyclosporine
(CsA) therapy is accompanied by the occurrence of hypercholesterolemia
and renal interstitial fibrosis. The present study investigates the effect of
dietary cholesterol on CsA-induced lipid disturbances in the rat and on
CsA nephrotoxicity. Since plasminogen activator inhibitor type I (PAl-i)
is a major inhibitor of matrix degradation and elevated plasma PAT-i
levels are reported to be associated with increased low-density lipoprotein
(LDL) cholesterol, PAl-i was examined in the kidneys of rats fed a
sodium-deficient diet, with or without cholesterol. After nine weeks, both
diet groups were subdivided into a CsA-treated group and a vehicle-
treated group. Although cholesterol feeding significantly aggravated CsA-
induced renal function impairment, CsA-induced histological lesions were
comparable in both diet groups. Cholesterol feeding significantly de-
creased high-density lipoprotein (HDL) cholesterol irrespective of the
treatment, while CsA treatment significantly elevated serum triglycerides
irrespective of the diet. Cholesterol feeding alone did not increase the
number of infiltrating cells in the renal interstitium. In contrast, in both
diet groups CsA treatment caused a significant influx of macrophages,
while combined treatment with CsA and cholesterol additionally elevated
the number of T-helper cells in the cortex. In all rats, PAl-i immunostain-
ing was found mainly in intracellular vesicles (lysosomes) in proximal
tubules, which stained most intensely in fibrotic areas of kidneys from
CsA-treated rats. Cholesterol feeding enhanced the CsA-induced eleva-
tion of renal PAl-i immunostaining to a significant level. These results
show that, although serum creatinine, PAT-i staining and T cell influx were
significantly increased in the cholesterol-fed CsA-treated group compared
to the other groups, renal CsA-induced histological lesions were not
influenced by cholesterol feeding after short-term (3 weeks) CsA admin-
istration. To what extent the more pronounced proximal tubular PAT-i
(inhibitor of matrix degradation) immunostaining in fibrotic areas in the
cortex of cholesterol-fed CsA-treated rats contributes to the progression
of CsA-induced renal fibrosis remains to be determined.
Since the introduction of CsA into clinical practice, it has
become apparent that nephrotoxicity significantly limits its use in
transplantation and in the treatment of autoimmune diseases [1].
Transient acute renal failure can be reversed after reduction or
discontinuation of CsA therapy [2]. More problematic is the
irreversible chronic form of CsA nephrotoxicity [1—4]. Chronic
CsA-induced pathological changes in the human kidney include
tubular atrophy, cellular infiltration of the renal interstitium,
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striped cortical interstitial fibrosis and prominent vascular injuly,
the so-called CsA-associated arteriolopathy [3—6]. These lesions
can be reproduced in different normotensive rat strains [7—11].
Application of salt depletion protocols (sodium-deficient diets
[121 or furosemide administration [113]) before and during CsA
treatment accelerates the development of chronic CsA-induced
lesions in the rat [7—il].
In the rat and in humans, irreversible striped cortical fibrosis is
the major chronic CsA-induced lesion [1—11]. Tubulointerstitial
fibrosis is the net result of increased extracellular matrix (ECM)
deposition and/or diminished ECM degradation. Two ECM de-
grading proteolytic systems, the plasminogen activator (PA)/
plasmin system and the matrix metalloproteinase system are likely
candidates to participate in matrix turnover to maintain renal
interstitial integrity. The PA/plasmin cascade can be blocked at
different levels. Although PAs can form complexes with several
members of the serine protease inhibitor (serpin) superfamily, the
main physiological PA inhibitor is PA inhibitor type I (PAT-i), a
glycoprotein produced by a variety of cell types [14, 151. Blockage
of plasminogen activation by PAT-i will inhibit all subsequent
plasmin-mediated actions, that is, activation of pro-matrix metal-
loproteinases and matrix degradation.
CsA-induced hypercholesterolemia aroused interest since Ba!-
lantyne et a! [16] reported increased plasma cholesterol levels in
amyotrophic lateral sclerosis patients on CsA therapy. CsA-
associated lipid disturbances in humans include increased triglyc-
eride and total cholesterol levels as well as increases in very-low-
density lipoprotein (VLDL) and low-density lipoprotein (LDL)
cholesterol concentrations [17—23]. CsA treatment of rats also
induces a significant elevation of LDL cholesterol [24]. In addi-
tion, CsA has been reported to have a prooxidant effect on plasma
LDL in renal transplant recipients [25, 26]. Oxidized LDL (ox-
LDL) is cytotoxic to endothelial cells, is chemotactic for circulat-
ing monocytes and can inhibit the motility of tissue macrophages
[27]. Furthermore, oxLDL is known to induce the synthesis of
fibrogenic cytokines and growth factors by macrophages, endo-
thelial and smooth muscle cells [27]. In vitro, components of
oxLDL can stimulate collagen gene expression in fibroblasts, thus
suggesting a direct link between matrix deposition and oxLDL as
well [27].
Recently, we and others demonstrated increased plasma PAT-i
levels in cyclosporine-treated renal allograft recipients [23, 28].
These higher systemic PAl-i levels may contribute to thrombo-
embolic complications and eventually to the impairment of renal
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Fig. 1. Experimental set-up. Abbreviations are:
Chol —, cholesterol-free sodium-deficient diet
based on AIN-76A; Chol+, sodium-deficient
diet based on AIN-76A supplemented with 2%
cholesterol; CsA+, injected daily s.c. with 15
mg CsAIkg body wt; CsA—, injected daily s.c.
with an isovolumetric dose of vehicle for CsA
(Cremophor EL).
function in CsA-treated patients. The elevation of systemic PAl-i
concentrations may result from the CsA-induced elevation of
LDL and VLDL levels, since in vitro studies have shown that LDL
and VLDL are potent stimulators of PAl-i release by endothelial
cells [29, 30]. A study in mice showed a dramatic increase of
(LDL+VLDL) cholesterol after coadministration of CsA and an
atherogenic diet [31]. Therefore, we hypothesized that the admin-
istration of dietary cholesterol to CsA-treated rats could lead to
altered renal PAl-i levels and an aggravation of renal function
impairment compared to CsA treatment alone.
Methods
Experimental model
Twenty-eight male Wistar rats with an initial weight of 200 to
250 g (Janssen Pharmaceuticals, Beerse, Belgium), were housed in
individual polypropylene cages under temperature-controlled
conditions in a constant dark-light cycle (7.00—19.00 hr light)
throughout the entire study period. Food intake and body wt were
monitored daily.
The experimental set-up is shown in Figure 1. The animals were
randomly assigned to two diet groups: the control diet group
(Chol—) received a sodium-deficient diet based on AIN-76A
(ICN Pharmaceuticals Inc., San Diego, CA, USA), and the
cholesterol-fed group (Chol+) received the same diet supple-
mented with 2% cholesterol. The diet pretreatment period ex-
tended up to nine weeks. After seven weeks, the animals were
fasted overnight and serum samples were collected from the tail
vein for measurement of serum creatinine levels and total and
LDL cholesterol. Nine weeks after initiation of the experiment,
the animals were again randomly subdivided into two treatment
groups: a CsA-treated group (CsA+) and a vehicle-treated group
(CsA—). Before starting the CsA treatment, weight-matched pairs
were selected from each treatment group within the same diet
group and during CsA treatment, these animals were pair-fed.
CsA (Sandlmmun i.v.; Sandoz Pharmaceuticals Company, Basel,
Switzerland) and its vehicle, Cremophor EL (Sandoz Pharmaceu-
ticals Company, Basel, Switzerland) were prediluted in I volume
of saline solution and sterilized. The CsA+ group received 15 mg
CsA/kg body wt daily, injected subcutaneously (s.c.) and the
CsA— group received an isovolumetric dose of Cremophor EL,
injected s.c. daily.
Before sacrifice, the rats were fasted overnight in metabolic
cages. The animals were anesthetized with ether. Blood was
drawn by cardiac puncture and partly collected over EDTA for
whole blood preparation and partly without additives for serum
preparation. Fasted serum samples were stored at —80°C until
further use. After prelevation of the rat kidneys, renal capsule and
fat tissue were removed, kidneys were rinsed in sterile saline and
processed for light microscopy.
Biochemical analyses
CsA trough levels were measured in whole blood with a
Fluorescence Polarization Immunoassay (FPIA) with a monoclo-
nal antibody to CsA (TDXITDX FL Cyclosporine Monoclonal
Whole Blood Assay; Abbott, Louvain-La-Neuve, Belgium). Uri-
nary and serum creatinine were measured using a modified Jaffé
colorimetric reaction (Creatinine Merckotest; Diagnostica Merck,
Darmstadt, Germany).
Total serum cholesterol was determined with the Monotest
Cholesterol CHOD-PAP method (Boehringer Mannheim, Mann-
heim, Germany). HDL cholesterol was measured after selective
precipitation of the LDL and VLDL fractions with polyethylene
glycol (Quantolip HDL; Immuno AG, Vienna, Austria). LDL
cholesterol levels were determined indirectly by measuring the
VLDL+ HDL cholesterol fraction after selective LDL precipita-
tion with a solution of dextran sulphate in Tris-HC1, pH 7.4
(Quantolip LDL; Immuno AG). LDL cholesterol was calculated
by substracting the (VLDL+HDL) cholesterol from total serum
cholesterol values. Serum triglycerides were analyzed enzymati-
cally with a glycerol kinase and a peroxidase dry slide technique,
without correction for glycerol (Kodak Ektachem Clinical Chem-
istry Slides TRIG; Eastman Kodak Company, Rochester, NY,
USA).
Morphological lesions
For light microscopy, renal tissue was fixed either in Dubosq-•
Brazil or formol-calcium fixative and embedded in paraffin. Renal
tissue was sectioned at 4 to 5 j.m, and periodic acid-Schiff reagent
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(PAS) and Sirius stainings were performed on Dubosq-Brazil
fixed tissue whereas Masson's trichrome staining was performed
on formol-calcium fixed tissue. To minimize variations caused by
handling tissue sections, in all instances in which tissues from
control and treated animals were compared, tissues were pro-
cessed and stained in parallel in the same buffers and antibody
mixtures.
Tubular damage in the cortex was evaluated in five randomly
selected low-power (X100) microscopic fields of PAS or Sirius
stained sections (total surface area evaluated per rat 9.6 mm2).
The following lesions were distinguished: (1) tubular atrophy, that
is, tubules with decreased diameter, decreased tubular lumen,
flattened epithelium, thickened or wrinkled basement membrane
and attenuation of the brush border; (2) vacuolization of tubular
epithelium; and (3) dilation of tubular lumen. Interstitial fibrosis,
defined as areas rich in extracellular matrix and atrophic tubules,
was graded semiquantitatively in trichrome stained renal sections
using a score system adapted from other groups involved in the
study of chronic cyclosporine nephropathy in the rat [7, 32]. Five
randomly chosen microscopic fields (magnification bOX) were
subdivided into 48 equal squares (total surface area evaluated per
rat 9.2 mm2). Each square received a score from 0 to 3: score 0
was assigned to normal basement membrane staining; score 1 was
given to squares containing less than 50% fibrotic tissue; score 2
was given to square sections with more than 50% fibrotic area;
and score 3 was assigned to squares entirely filled with atrophic
tubules and extracellular matrix. The mean of the scores given to
240 evaluated squares was calculated per rat and the results were
expressed as fibrosis score per square. Sections were evaluated
without knowledge of the group affiliation of the individual rat.
Cellular proliferation
In order to evaluate cellular proliferation and to localize
proliferating cells, PAS was combined with immunostaining for
the proliferating cell nuclear antigen (PCNA [33]) using the PC1O
monoclonal antibody (DAKO, Denmark) on methacarn-fixed
renal tissue. All PCNA-positive nuclei within 20 randomly se-
lected cortical microscopic fields were counted (magnification
x200, total surface area evaluated per rat 9 mm2). Proliferation
was examined separately in intact tubules, in damaged tubules
(atrophic tubules, tubules with dilated lumen and tubules with
vacuolized epithelial cells), in glomeruli and in the renal cortical
interstitium. At least 40 glomerular cross sections were evaluated
per rat. Results were expressed as absolute numbers of PCNA+
cells per mm2 cortex or per glomerular cross section. Sections
were evaluated without knowledge of the group affiliation of the
individual rat.
Phenolyping of interstitial inflammatory cells
Pan-leukocyte and macrophage stainings were performed on
methacarn-fixed, paraffin-embedded renal tissue. Leukocytes
were stained with the OX-i monoclonal antibody (Serotec, Ox-
ford, UK) that recognizes the rat leukocyte common antigen
(LCA) present on all marrow-derived leukocytes, that is, thymo-
cytes, bone marrow cells, peripheral lymphocytes and macro-
phages [3I. Macrophages were identified with the EDI mono-
clonal antibody (Serotec), which is directed to a cytoplasmic
antigen of monocytes and tissue macrophages, but also recognizes
dendritic cells [35]. Immunohistochemical detection of lympho-
cytes was performed on 5 im renal tissue cryosections prefixed in
formol-calcium. The W3/25 monoclonal antibody (Serotec) used
to detect T-helper cells is directed to the rat CD4-equivalent [36].
The OX-8 monoclonal antibody (Serotec) was used to detect
T-suppressor/cytotoxic and natural killer cells, and is directed to
the rat CD8-equivalent [36]. B lymphocytes were counted in
sections stained with the OX-4 monoclonal antibody (Harlan
Sera-Lab Ltd., Sussex, UK), which recognizes the Ia marker
present on B cells and dendritic cells [37]. Nuclei were counter-
stained with methyl green.
Cells showing distinct immunoreaction were counted in 10
randomly chosen areas (magnification X 200, total surface area
evaluated per rat 4.5 mm2) in the superficial cortex, and in 10
random areas in the deeper cortical area. Per renal section at least
25 glomerular profiles were examined for infiltrating cells. Inflam-
matory cells not contained within large blood vessels or glomer-
ular cross sections were considered to be interstitial. Results were
expressed as absolute numbers of immunoreactive cells per mni2
or per glomerular cross section. Sections were evaluated without
knowledge of the group affiliation of the individual rat.
Immunohistochemical staining for PAl-i
Renal tissue fixed in formol-calcium and embedded in paraffin
was sectioned at 4 j.m and mounted on poly-L-lysine coated
microscope slides, deparaffinized and rehydrated. To unmask
PAl-I antigens, renal sections were incubated at room tempera-
ture with a 0.003% solution of trypsin III (Sigma Chemie,
Bornem, Belgium) in 0.01 M Tris-HCI, pH 7.3, in 0.9% NaCl
containing 1 mM CaCl2 and washed with Tris saline buffer (TSB:
10 mM Tris-HC1, pH 7.6, 0.9% NaCl, 0.1% Triton X-iOO and
0.004% merthiolate). Mouse anti-human PAT-I monoclonal anti-
body, MA-7F5 (provided by Dr. R.H. Lijnen and Dr. P. Declerck,
Center for Molecular and Vascular Biology, Leuven, Belgium
[38]) was applied for overnight incubation. After washing in TSB,
sections were treated with methanol and 0.03% H2O2 to quench
endogeneous peroxidase activity, and incubated with biotinylated
horse anti-mouse serum (ABC kit; Vector Laboratories Inc.,
Burlingame, VT, USA). To prevent a cross-reaction of horse
anti-mouse serum with rat IgG, 5% normal rat serum was added
to the secondary antibody mixture 30 minutes before use. After
washing in TSB, the avidin-biotin peroxidase complex (ABC kit;
Vector Laboratories Inc.) was added and color development was
performed with AEC as chromogen in the presence of 0.006%
H202. Controls for background staining were obtained by per-
forming parallel stainings in which the primary antibody was
omitted. Specificity of the primary antibody was examined by
staining with normal mouse serum in different dilutions, and
confirmed in pre-adsorption experiments on serial sections in
which purified PAl-i antigen of human origin (PAT-i antigen
standard, Innotest PAl-i; Innogenetics, Ghent, Belgium) was
added to the antibody solution in a final concentration ranging
from 2.5 to 50 ng/ml and incubated for one hour at room
temperature. To identify PAl-i immunoreactive cells, PAl-i
immunostaining was combined with PAS histological stain on
formol-calcium-fixed renal tissue and the chromogen 3,3'-diami-
nobenzidene (DAB) was used to visualize antigen-antibody stain-
ing.
To evaluate the focal PAT-i immunostaining, stained sections
of all experimental groups were blinded and considered as a single
sample for purposes of ranking. The sections were ranked, taking
into account a number of factors including: (1) the number of
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positive vesicles per microscopic field; (2) vesicle-size; (3) the
intensity of the staining; (4) the cortical surface containing PAl-I
immunoreactive vesicles. The section with the weakest PAl-i
immunostaining received rank 1. Sections with more extensive
PAl-i antigen staining were given progressively higher ranks.
Ranking was performed by one investigator (CD) on three
separate occasions, and by an independent investigator (GV) on a
single occasion. The correlation between the repeated rankings
and the correlation between the observations of two investigators
were high (Rs > 0.91 and Rs > 0.76, respectively, P < 0.0001).
Therefore, only the results obtained by investigator CD were used
for further analysis.
Statistics
Results are expressed as mean SD, unless stated otherwise.
Differences between the means of two groups were analyzed with
the t-test for independent samples. Effects of CsA treatment and
cholesterol feeding were analyzed with multiple ANOVA
(MANOVA), followed by group-to-group comparisons with the
Student-Newman-Keuls test with a significance level of 0.05.
Ranking data were tested for overall differences using the
Kruskal-Wallis test, followed by post-hoc comparison testing
using the Mann Whitney U-test, significance level 0.05. Spear-
man's rank correlation test was used to establish correlations
(with correlation coefficients Rs). Statistical analysis was com-
puted using two software packages: SPSS (release 6.0) and
STATISTICA (release 4.3) for MS Windows.
Results
Body weight and renal function
There was no mortality during the course of the study. Pair-
feeding was successful since all animals had comparable body
weights at the time of sacrifice. Seven weeks after the initiation of
the diet pretreatment, renal function was not influenced by the
type of diet as shown by the serum creatinine levels of both diet
groups (Chol—, 0.42 0.03 mg/dI vs. Chol+, 0.43 0.06 mgldl).
After three weeks of CsA treatment both CsA+ groups had
significantly elevated serum creatinine levels compared to the
vehicle-treated groups (Fig. 2). Cholesterol feeding aggravated
renal function impairment, as shown by the significantly increased
serum creatinine levels in the Chol+CsA+ group, compared to
the Chol—CsA+ group. CsA whole blood levels were significantly
lower (1-test for independent samples, P < 0.05) in the
Chol+CsA+ group (4562 829 nglml) compared to the
Chol—CsA+ group (6092 549 ng/ml).
Serum lipids
Feeding rats a sodium-deficient diet supplemented with 2%
cholesterol during seven weeks, did not result in an increase of
total cholesterol (Chol—, 106.1 25.8 mg/dl vs. Chol+, 97.5
26.9 mg/dl). The LDL cholesterol fraction, however, showed a
tendency towards an increase in cholesterol-fed rats (Chol—,
6.4 3.1 mgldl vs. Chol+, 10.2 9.7 mg/dl). Serum lipids after
three weeks CsA or vehicle treatment are represented in Figure 3.
Cholesterol feeding significantly decreased the serum HDL cho-
lesterol fraction in both vehicle-treated and CsA-treated rats (P
0.000 1). There was a tendency towards an elevation of VLDL and
LDL cholesterol levels after CsA treatment, irrespective of the
diet administered. VLDL cholesterol levels were significantly
n=7 5 7 7
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Fig. 2. Serum creatinine levels (mg/dl) after 3 weeks of CsA treatment
(CsA +) or vehicle treatment (CsA —). A sodium-deficient cholesterol-free
diet (Chol—) and a sodium-deficient diet enriched with 2% cholesterol
(Chol+) were administered during a period of 9 weeks before the
initiation of the CsA treatment and during the CsA treatment. Each bar
represents the mean SD. Symbols are: () vehicle-treated; (L:) CsA
treated; * < 0.05.
increased in the ChoI—CsA+ group (Fig. 3). The result of these
effects on the different cholesterol fractions was a significant
elevation of total cholesterol levels in the Chol—CsA+ group
compared to all other groups (P = 0.0001). Serum triglycerides
levels were significantly increased in both CsA+ groups, and were
highest in the Chol—CsA+ group (Fig. 3).
Morphological lesions
CsA-induced renal injury was largely confined to the cortical
area and consisted of foci of atrophic tubules, surrounded by
increased extracellular matrix and inflammatory cells. Most of the
atrophic tubules had thick, wrinkled basement membranes. In
PAS and trichrome stained sections, epithelial cells of dilated
tubules were optically translucent, containing small isometric
vacuoles. In the triangular scarred subcapsular areas, tubular
basement membranes sometimes lost their integrity, rendering
the identification of tubules difficult. Alterations of cells in dilated
and atrophic tubules precluded exact classification of the cell type.
Tubules with large vacuoles were found adjacent to atrophic foci.
Tubular microcalcifications were observed in the medulla of
(CsA+)-animals. Some of the superficial fibrotic areas extended
towards the inner cortex to form "striped" scarred areas. No
glomerular or arterial renal lesions could he detected.
The percentage of atrophic tubules was significantly increased
after three weeks of CsA treatment (P < 0.00001). An average of
27% of all cortical tubules in kidneys from CsA+ rats were
atrophic (Fig. 4). Vacuolization and dilation of tubules (Fig. 4),
were significantly increased after CsA treatment (P < 0.00001)
and were observed in 12% of all cortical tubules of CsA+ rats.
Administration of a cholesterol-supplemented diet alone did not
cause tubulointerstitial fibrosis. The fibrosis score of both CsA-
treated groups was higher than the fibrosis score of both vehicle-
treated groups (Fig. 4). CsA-associated renal fibrosis was not
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Fig. 3. Serum lipoprotein cholesterol fractions
and serum triglycerides after 3 weeks of treatment100 with 15 mg CsA/kg body wt (CsA +) or with an
isovolumetric dose of Cremophor EL (GsA —).
Each bar represents the mean SD. Symbols
0 are: () vehicle-treated; (tV) CsA-treated; *p <
N— 7 5 7 7 0.05. Abbreviations are: Chol—, cholesterol-free—
sodium-deficient diet; Chol+, sodium-deficient
Chol— Chol+ diet supplemented with 2% cholesterol.
aggravated by feeding the rats a diet supplemented with 2% adjacent intact areas (Fig. 5B). CsA treatment significantly in-
cholesterol during a period of 12 weeks (Fig. 4). creased the number of PCNA+ cells in injured tubules, that is,
atrophic tubules, tubules with vacuolized epithelium and tubules
Cellular proliferation with a dilated lumen (Fig. 6). In intact tubules, cellular prolifer-
Cellular proliferation (PCNA positivity) was pronounced in the ation was significantly higher in the Chol—CsA+ group compared
interstitial compartment and in injured tubules in scarred cortical to all other experimental groups (Fig. 6). Proliferation of inter-
areas of CsA-treated rats, whereas it was almost absent in stitial cells was significantly increased after CsA treatment (Figs.
'ft.)
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Fig. 4. Quantification of morphological lesions
in the renal cortex and fibrosis score per square.
Tubular atrophy, vacuolization of tubular
epithelium and dilation of tubules are expressed
as the percentage of damaged tubules. Fibrosis
was graded (Masson's trichrome staining) using
the following score system: 0 = intact renal
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5 B, C, and 6). CsA significantly increased the number of PCNA+
cells in glomeruli irrespective of the diet treatment, while admin-
istration of a cholesterol-supplemented diet during CsA treatment
additionally stimulated cell proliferation in the glomerular com-
partment (Fig. 6).
Phenolyping of inflammatory cells
Although infiltration was slightly higher in the superficial cortex
than in deeper cortical areas, significant group-to-group differ-
ences were the same in both cortical areas. Therefore, the results
were expressed as number of inflammatory cells per mm2 renal
cortex. Kidneys from vehicle-treated rats contained very few ED1
positive cells but much more W3/25 immunoreactive cells (Fig. 7).
Dietary cholesterol in itself did not cause an influx of inflamma-
tory cells (Fig. 7). Irrespective of the diet, CsA caused a significant
increase of macrophages (EDI +), T-suppressor/cytotoxic cells
(OX-8+) and B cells (OX-4+), but the number of T-helper cells
(W3125+) was not significantly increased when CsA was admin-
istered alone (Fig. 7). However, when the CsA-treated rats were
given a cholesterol-supplemented diet, the number of tubuloin-
terstitial T cells, particularly of T-helper cells, significantly in-
creased in both cortical areas (Fig. 7). Neutrophils were sparse in
all four experimental groups. In glomeruli, CsA treatment caused
a significant increase of ED1+ cells, which was not influenced by
the administration of dietary cholesterol: glomerular cross sec-
tions from (C5A+)-rats contained an average of 4 to 6 EDI+
cells.
Immunohistochemical staining for PAl-i
Negative controls, performed by immunostaining in which the
primary antibody was omitted or in which normal mouse serum
was used as a source of mouse immunoglobulins, produced no
signal (data not shown). Pre-adsorption of the primary antibody
using increasing amounts of purified human PAl-i caused immu--
nohistochemical signals to disappear (data not shown). Therefore,
the immunohistochemical signals obtained with the monoclonal
antibody MA-7F5 can be considered to he specific for PAl-i
antigen.
PAl-i was immunodetectable in kidneys from all experimental
groups. PAl-I immunoreactive signals were most prominent in
the cortex. Immunoloealization of PAT-i was comparable in both
vehicle-treated groups: intense PAl-i immunoreactive vesicles
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Furthermore, both stainings were more intense in the Si and S2
portions of the proximal tubuli in the cortex than in the S3
segment in the outer stripe of the outer medulla (Fig. 8B). This
suggests that the PAl-i immunoreactivity has a lysosomal local-
ization. PAT-i positivity was also found as homogeneous cytoplas-
mic staining in arterial smooth muscle cells and in visceral
epithelial cells (Fig. 8C). As in both vehicle-treated groups, PAl-i
immunoreactivity was present in kidneys of both CsA-treated
groups in intracellular vesicles in proximal tubular cells, and as a
cytoplasmic staining of arterial smooth muscle cells and visceral
epithelial cells. However, three weeks of CsA treatment with or
without the administration of dietary cholesterol resulted in more
pronounced PAl-I staining of vesicles in damaged (atrophic,
dilated) proximal tubules located within fibrotic areas (Fig. 8D).
The majority of the atrophic and dilated tubules in these damaged
areas contained large amounts of PAl-i immunoreactive material
within sometimes large vesicles (Fig. 8 D, E); a few of them,
however, contained almost no PAl-I positive vesicles (Fig. 8F). In
both CsA-treated groups, PAT-i immunolocalization was compa-
rable. In a limited number of sections of all four experimental
groups, collecting and papillary ducts were stained for PAl-i at
the apical side. Cytoplasmic PAl-i immunostaining of glomerular
and smooth muscle cells, was no longer visible in combined
PAI/PAS stainings (Fig. 8F), presumably due to the use of the less
sensitive DAB-substrate to visualize antigen-antibody binding.
Semiquantitative analysis of PAT-i immunostained renal sec-
tions showed a tendency towards an increase of PAl-i staining
after CsA treatment that was elevated to a significant level by the
administration of dietary cholesterol (Table 1). No effect of
cyclosporine treatment and cholesterol feeding on the cytoplasmic
staining of both smooth muscle cells and visceral epithelium was
found.
Discussion
Fig. 5. PASIPCNA staining of renal sections of a vehicle-treated cholesterol-
frd rat (A) and a GsA-treated cholesterol-fed rat (B, C). A. The cortex of the
vehicle-treated rat contains very few PCNA immunoreactive cells. B. Note
the striking PCNA positivity in the damaged tubules and in the interstitial
space of a subcapsular injured focus compared to the few PCNA immu-
noreactive cells found in an adjacent intact area (left hand corner) in the
renal cortex of a CsA-treated rat. C. A detail from micrograph B shows
PCNA positive nuclei in epithelial cells of atrophic tubules and tubules
with a dilatcd lumen and interstitial cells (magnification A and B, X80; C,
x281).
were observed in cortical tubules and appeared to be confined to
proximal tubular cells (Fig. 8A). Sections stained for the lysoso-
mal enzyme acid phosphatase [39] were compared with PAl-I
stained sections (data not shown). Acid phosphatase and PAl-i
staining demonstrated a comparable intracellular localization.
The CsA-induced tubulointerstitial lesions observed in our
model were consistent with those in previously described rat
models of chronic CsA nephrotoxicity [7, 9, 11]. After CsA
treatment, renal PAT-i staining showed a tendency towards an
increase in fibrotic areas, and dietary cholesterol accentuated this
effect to a significant level. In addition, cholesterol feeding
aggravated CsA-induced renal function impairment.
Cholesterol feeding alone did not influence renal function, but
combined CsA therapy and dietary cholesterol supplementation
resulted in more pronounced renal function impairment. CsA
mediates renal vasoconstriction through various vasoactive sub-
stances including endothelin and thromboxanes [40]. As dietary
cholesterol and cholic acid have been shown to enhance renal
thromboxane synthesis [411, the combination of CsA and dietary
cholesterol may have enhanced thromboxane production com-
pared to GsA treatment alone. The more pronounced decline of
renal function in the cholesterol-fed GsA-treated group was not
the consequence of higher CsA whole-blood levels. On the
contrary, cholesterol feeding resulted in lower CsA whole-blood
levels. The lower levels of circulating CsA in the cholesterol-fed
GsA-treated group may be due to the cholesterol-induced de-
crease of serum HDL cholesterol. in blood, up to 80% of GsA is
transported in various lipoprotein fractions [421 that are metabo-
lized at different rates [20]. Since GsA preferentially incorporates
into triglyceride-poor HDL particles that are metabolized rela-
tively slower than the triglyceride-rich VLDL and LDL particles
250
*
200
150
• - 100
• • 50
0
Chol— ChoI+ Chol— ChoI+
Interstitium Glomeruli
10
8
6
4
2
0
*
*n
:ii1
-t
I
-
*P
0
Duymelinck et al. Blood lipids and PAZ-i in GsA nephropathy 1825
Fig. 6. Quantification of cell proliferation in the
cortex. Proliferation was quantified separately in
CsA-injured tubules (atrophic tubules, dilated
tubules and tubules with vacuolized
epithelium), in intact tubules, in the cortical
interstitial space, and in glomerular cross
sections. Results are expressed as the number
of PCNA positive cells per mm2 cortex or per
glomerular cross section. Each bar represents
the mean so. Symbols are: () vehicle-
treated; (i2 CsA-treated; *p < 0.05.
Abbreviations are: Chol—, cholesterol-free
sodium-deficient diet; Chol +, sodium-deficient
diet supplemented with 2% cholesterol. Note
the difference in scale in the bar graph
representing the data of glomerular PCNA
positivity.
[22, 42], high HDL levels may maintain elevated CsA whole-blood
levels. On the other hand, dietaiy cholesterol is known to increase
the hepatic transcription of rat 7a-hydroxylase [43], a cytochrome
P450 enzyme that shares many features with the mixed-function
cytochrome P450 monoxygenases [44]. Since substances interfer-
ing with the P450 pathway responsible for the conversion of
cholesterol to bile acids also interfere with CsA catabolism, it is
possible that dietary cholesterol in turn increased the hepatic
expression of cytochrome P450 A3, thereby increasing the catab-
olism of the CsA molecule. Finally, incorporation of CsA into
lipid bilayers is greatly influenced by membrane fluidity. A
decreased cholesterol/phospholipid ratio (increased fluidity) fa-
vors CsA insertion [45]. However, since total cholesterol levels
were not influenced in our experimental setting, it is unlikely that
the cholesterol content of cell membranes was altered to a degree
in which GsA incorporation was affected.
The aggravation of renal dysfunction after combined treatment
with CsA and dietary cholesterol was not reflected by an increase
of CsA-induced renal histopathological lesions in our model. In a
recent paper, Eddy, Liu and McCulloch [46] studied the effect of
pronounced diet-induced hypercholesterolemia on the develop-
ment of tubulointerstitial fibrosis in the uninephrectomized rat.
After 12 weeks, the hypercholesterolemic rats had a significantly
increased total kidney collagen content compared to uninephrec-
tomized rats fed standard chow. In our model, in which total
cholesterol levels were not increased after cholesterol administra-
tion, the lack of differences between the fibrosis score of the diet
groups may be due to the limited duration of our experiment.
The significantly increased PCNA positivity of tubular and
interstitial cells in focal injured areas in kidneys of CsA-treated
rats in our model was in agreement with reports by other groups
[7]. However, when rats were given a higher dose of CsA during
a shorter period, proliferation (measured as [3H] thymidine
incorporation) was reported to be mainly confined to the inter-
stitial compartment [10]. In our experimental setting, CsA stim-
ulated PCNA expression in injured tubules and in the interstitial
compartment. Mitotic figures, however, were rarely seen in atro-
phic or dilated tubules. Since PCNA is an auxiliary protein for
DNA polymerase 5 and is required for both DNA replication and
DNA repair [7I, its expression may be a very sensitive indicator
of cell repair following CsA-mediated cell injury [48]. The atro-
phic and dilated tubules that show extensive PCNA positivity in
our model may have the potential to regenerate after discontin-
uation of the CsA treatment at this stage. The PCNA immuno-
reactive interstitial cells are most likely T-helper cells and mac-
rophages, since they were the predominant cell type found in the
cortical interstitium of CsA-treated rats. Recently, macrophages
have been shown to be capable of proliferating [49]. This was
confirmed in our model by double stainings for EDI and PCNA
(data not shown).
Whether leukocyte infiltration precedes the formation of pro-
gressive renal injury or whether inflammatory cells are recruited
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Fig. 7. Quantification of tnflltratrng cells in the
600 cortical interstitiunz. Results are expressed as the
number of immunoreactive cells/mm2 cortical
500 area. The different inflammatory subsets were
identified using the following monoclonal
400 antibodies: OX-i (leukocytes); ED1
(monocytes/macrophages and dendritic cells);300 W3/25 (T-helper cells); OX-8 (T-suppressor/
cytotoxic cells and natural killer cells); and OX-200 4 (B lymphocytes and dendritic cells). Each bar
represents the mean SD. Symbols are ()100
vehicle-treated; () CsA-treated; < 0.05.
Abbreviations are: Chol -, cholesterol-free0 sodium-deficient diet; Chol+, sodium-deficient
Chol— Chol+ diet supplemented with 2% cholesterol.
-
Fig. 8. Immunohistochemical PAZ-I staining of formol-calcium-fired paraffin-embedded renal tissue. A, B, D-F: PAl-i immunostaining combined with
PAS. C: PAl-i immunostaining with hematoxylin nuclear staining. A-C: Renal sections from a vehicle-treated rat fed a cholesterol-supplemented diet.
D-F: Renal sections from a CsA-treated rat fed a cholesterol-supplemented diet. A. PAT-i immunoreactive vesicles in normal proximal tubular cells.
B. PAT-i positive vesicles in the Si and S2 segments of the proximal tubules are intensely stained and large (top half of micrograph), while PAT-i
immunostained vesicles in the S3 portion of the proximal tubules are smaller and sparse (arrows, bottom half of the micrograph). C. Cytoplasmic PAT-i
immunostaining in arteriolar smooth muscle cells (large arrows) and in visceral epithelial cells (small arrows). D. Renal cortex of CsA-treated rat. PAl-I
vesicle staining in intact proximal tubules (bottom left corner) is comparable with the PAl-i staining observed in vehicle-treated rats. Injured tubules
contained within fibrotic areas contain large and intensely stained PAl-i immunoreactive vesicles (arrows). E. Atrophic proximal tubules containing
large amounts of intensely stained PAT-i immunoreactive vesicles, which are sometimes as large as nuclei (arrows). F. Intact proximal tubules in the
cortex of a CsA treated rat containing PAT-I positive vesicles with a comparable size to the PAT-i immunoreactive vesicles found in proximal tubular
cells of a vehicle-treated rat in micrograph A. Some of the atrophic tubules contain very few or no PAT-i immunoreactive vesicles (arrows) (A, B, E,
F, X4i4; C, Xi035; D, X104).
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Table 1. Ranking of renal sections immunostained for PAt-i
Groups
Mean rank
Ranking 1 Ranking 2 Ranking 3
Chol—CsA—
Chol—CsA+
Chol+CsA—
Chol+CsA+
8.5
12.4
16.5
206a,h
8.4
13.1
15.0
215a,b
8.0
13.5
15.2
21.3"
Ranking was performed on 3 separate occasions (rankings 1, 2 and 3) by
researcher CD; ranking data were analyzed for overall differences with the
Kruskal-Wallis test and are expressed as mean group ranks. The correla-
tion between repeated rankings was very high: ranking I vs. ranking 2, Rs
0.93 (P C 0.0001); ranking I vs. ranking 3, Rs 0.91 (P < 0.0001); ranking
2 vs. ranking 3, Rs 0.97 (P C 0.0001).
a Significantly different from Chol—CsA--- group, P C 0.05, Mann-
Whitney U-test.
Significantly different from Chol—CsA+ group, P C 0.05, Mann-
Whitney U-test.
to damaged sites in the kidney, remains to be explored. Young et
al [7] observed a striking influx of ED1 immunoreactive cells in
the rat kidney as soon as day 5 after initiation of CsA treatment,
which preceded cortical fibrogenesis. This suggests that macro-
phages could play an active role in the progression of CsA-
mediated renal scarring since macrophages release a number of
factors that promote fibroblast proliferation and collagen synthe-
sis such as TGF-p, IL-I, TNF-a and PDGF [50].
PAl-i is a local tissue-associated inhibitor of proteolysis, local-
ized at sites of vascular injury or tissue disruption and inflamma-
tion. In our experimental setting, PAl-i antigen was localized in
the normal rat kidney in vesicles in proximal tubular cells and in
the cytoplasm of visceral epithelium and smooth muscle cells. The
following arguments suggest that this staining reflects the actual
immunolocalization of PAl-i: (1) negative controls for the stain-
ing (omission of the primary antibody and the use of normal
mouse serum as source of murine immunoglobulins) produced no
immunoreactive signals; (2) pre-adsorption of the primary anti-
body to increasing amounts of purified human antigen resulted in
a progressive decrease of the immunoreactive PAl-i signals; and
(3) the vesicular staining pattern observed in proximal tubular
cells could be clearly differentiated from the cytoplasmic staining
pattern in visceral epithelial and smooth muscle cells.
Reports on PAl-I immunostaining of the normal kidney are
conflicting. Indirect immunofluorescent PAl-I staining of human
renal tissue, without microscopic abnormalities, revealed strong
PAl-i expression within cytoplasm and foot processes of glomer-
ular cells and weak PAl-i immunoreactivity in mesangial cells,
glomerular capillaries and interstitial cells [51]. Rondeau et al
[52], however, reported the absence of significant immunofluores-
eenee with a polyclonal antibody against human PAl-i in normal
human kidneys. Eddy et al [53] were unable to detect PAl-I
antigen in renal tissue from control rats. Using a polyclonal rabbit
anti-rat PAl-i antibody, Tomooka et al [54] and Barnes, Mitchell
and Torres [55] detected slight mesangial staining for PAl-I in the
kidneys of untreated Sprague-Dawley rats. In the mouse kidney,
renal papilla and medial smooth muscle cells of renal arteries
were PAl-i positive [56]. The discrepancy between our findings
and all these observations may be ascribed to species differences,
differences in tissue processing, the fact that different antibodies
were used as well as different staining techniques, with varying
sensitivity. It is conceivable that the use of antibodies directed
against different epitopes on PAl-i could lead to different staining
patterns. The antibody used in the present study is able to
recognize free (active and latent) and (to a lesser extent) tPA-
complexed PAl-i in human plasma [38]. Since rat PAl-i is a
glycoprotein with a single cysteine residue, no disulfide bridges
stabilize its tertiairy structure [57]. Therefore, PAl-i can adopt
different conformations in which neoantigenic epitopes are gen-
erated, that is, latent PAl-i [58], PAl-i covalently bound to PAs
[59] and cleaved inactive substrate PAl-i [59].
The PAl-i immunoreaetive vesicles are most likely lysosomes
since PAl-i and acid phosphatase (a lysosomal enzyme) have
comparable staining patterns. Both stainings are most intense
within the Si and S2 segments of proximal tubules in the cortex,
and less pronounced in the S3 segment in the outer stripe of the
outer medulla. This corresponds with the fact that rat proximal
tubular cells of the Si and S2 segments have a well-developed
vaeuolar lysosomal system, while in epithelial cells of the S3
portion of the proximal tubule lysosomes are small and sparse
[60]. In addition, lysosomes as large as nuclei have been demon-
strated with the acid phosphatase stain in focally distributed
proximal tubular cells of CsA-treated rats [39]. This is consistent
with the large PAl-i positive vesicles we found in proximal tubular
cells located within fibrotic areas in the cortex of CsA-treated rats.
The PAl-i immunoreactivity observed in proximal tubular lyso-
somes may consist of internalized PA:PAI complexes. PA:PA1
complexes are internalized after binding to the multiligand endo-
cytotic receptor a2-macroglobulin receptor/low density lipopro-
tein receptor-related protein (a2MR/LRP) [61] or glycoprotein
330 (gp330) in the kidney [62]. In the normal rat kidney, gp330 is
mainly expressed by proximal tubular cells [62], the cell type in
which the PAl-i positive vesicles were observed. Furthermore, the
expression of gp330 is more pronounced in the Si and S2
segments than in the S3 segment [62], which is consistent with the
more abundant presence of large PAl-i positive vesicles in the Si
and S2 segments and the lower intensity of PAl-i vesicle-staining
in the S3 portion of the proximal tubule observed in our experi-
mental set-up.
Whether renal PAl-i observed in vesicles was locally produced
or reabsorbed from the filtrate remains to be determined. Free
uncomplexed PAl-i (50 to 54 kDa) [57] may be partially filtered
and reabsorbed by proximal tubular cells. However, in plasma,
PAl-i binds to vitronectin, an adhesive glycoprotein that stabilizes
PA! in its active conformation [63]. Complexes of PAl-i with
vitronectin and vitronectin multimers (> 150 kDa) [63] are not
likely to pass through the glomerular sieve. Furthermore, a pilot
rat study conducted by our group showed that plasma PAT-i levels
were not increased after three weeks of CsA treatment (data not
shown). Therefore, the PAT-i observed in proximal tubular cells
may be locally synthetized in the kidney. Although PAl-i mRNA
was not detectable in in situ hybridizations of control renal tissue
of rat and humans [55, 64], Eddy et a! [53] and Shihab et al [32]
were able to detect PAl-i mRNA in renal extracts from kidneys
from control rats. Furthermore, immunostaining and in situ
hybridization studies have indicated that tubular cells were the
main site of PAT-i expression within the tubulointerstitium of rats
with puromycin aminonueleoside nephrosis [65]. In the protein-
overload proteinuria model [53], PAT-I mRNA expression is
significantly increased in kidneys from the proteinuric rats at the
time of increased renal matrix protein expression. PAl-i protein
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was immunolocalized in a few cortical tubules and in the wall of
large vessels of proteinuric animals, while PAl-i immunoreactivity
was absent in kidneys from control rats [53]. This suggests that at
least in this rat model of renal scarring, increased tubular PAl-i
immunostaining was due to increased renal PAl-I synthesis. In
the model of diet-induced hypercholesterolemia in uninephrecto-
mized rats, the increase of PAl-i gene expression was transient
and preceded the development of tubulointerstitial lesions [46].
Finally, Shihab et at [32] demonstrated a progressive increase of
renal PAT-i mRNA expression in rats treated with 15 mg CsA!kg
body wt as early as seven days after the initiation of CsA
treatment. Based on these data, it is unlikely that the large PAl-I
immunoreactive vesicles observed in injured tubules in the fibrotic
cortical areas of CsA-treated rats in our model are composed
solely of PAT-i antigen reabsorbed from the filtrate. Furthermore,
in our model, atrophic tubules, which are less functional than
intact cells, and dilated tubules, which have a reduced capability to
reabsorb due the loss of their brush border, often contain large
amounts of PAT-i positive material.
In summary, in our experimental set-up dietary cholesterol
increased CsA-induced renal function impairment, but had no
effect on CsA-induced renal histopathological changes in the
kidney. Three weeks of CsA treatment caused more pronounced
PAT-i staining in damaged proximal tubules localized within
fibrotic areas. Combined cyclosporine treatment and cholesterol
feeding accentuated the elevation of PAT-i immunoreactivity to a
significant level. This could implicate a local decrease of intralu-
minal protein degradation and matrix turnover, and may there-
fore contribute to the progression of chronic renal scarring in the
cyclosporine-treated rat.
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